GlassScriptPhysician profile
Hunaid Hasan
NPI 1578983581
$20,029.81
in general payments reported to CMS, 2019-2025
57 companies · $4,315 in 2025
The $4,315 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,670 · 2020: $232 · 2021: $2,654 · 2022: $2,802 · 2023: $3,065 · 2024: $3,292 · 2025: $4,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,672.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $2,418.52 | 2019 | |
| Ucb, INC. | $1,588.36 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $1,347.87 | 2021-2025 | |
| Biogen, INC. | $1,236.05 | 2020-2025 | Tysabri, Vumerity, Avonex |
| Novartis Pharmaceuticals Corporation | $845.98 | 2020-2025 | |
| Sk Life Science, INC. | $767.79 | 2020-2025 | |
| Livanova USA, INC. | $734.64 | 2019 | |
| Pfizer INC. | $733.72 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $729.64 | 2019-2025 | Ingrezza, Ongentys |
| Eisai INC. | $608.12 | 2021-2025 | |
| Genentech USA, INC. | $600.49 | 2021-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $578.82 | 2020-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Celgene Corporation | $544.11 | 2021-2025 | Zeposia |
| Acadia Pharmaceuticals INC | $490.97 | 2019-2025 | Nuplazid |
| Lilly USA, LLC | $472.32 | 2021-2025 | Emgality, Kisunla, Reyvow |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $467.06 | 2022-2025 | Ultomiris, Koselugo |
| Jazz Pharmaceuticals INC. | $358.71 | 2022-2025 | |
| Neurelis, INC. | $354.96 | 2020-2025 | Valtoco |
| Argenx US, INC. | $351.91 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $318.62 | 2022-2025 | |
| Mdd US Operations, LLC | $293.50 | 2019-2024 | Apokyn |
| Lundbeck LLC | $292.83 | 2023-2025 | Vyepti |
| Tg Therapeutics, INC. | $278.31 | 2025 | |
| Medtronic, INC. | $242.36 | 2021-2025 | Activos 10 Bone Cement |
| Sumitomo Pharma America, INC. | $232.24 | 2023-2024 | Aptiom |
| Kyowa Kirin, INC. | $217.60 | 2020-2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $216.73 | 2023-2025 | Rexulti, Nuedexta |
| Amgen INC. | $213.31 | 2021-2022 | |
| Tanabe Pharma America, INC. | $187.23 | 2022-2025 | Radicava |
| Catalyst Pharmaceuticals, INC. | $173.38 | 2022-2025 | Fycompa |
| Biohaven Pharmaceuticals, INC. | $169.66 | 2021 | |
| Aucta Pharmaceuticals, INC. | $167.95 | 2024-2025 | Motpoly Xr |
| Acorda Therapeutics, INC | $159.94 | 2019-2021 | |
| Allergan, INC. | $152.78 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $122.35 | 2022-2025 | Qelbree |
| Horizon Therapeutics Plc | $121.99 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $119.03 | 2020-2022 | |
| Zogenix INC. | $118.94 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.15 | 2022 | |
| Janssen Pharmaceuticals, INC | $99.99 | 2022-2023 | Ponvory |
| Emd Serono, INC. | $98.31 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $91.68 | 2021-2022 | |
| Harmony Biosciences LLC | $77.73 | 2021-2022 | |
| Greenwich Biosciences, INC. | $64.27 | 2020-2021 | |
| Csl Behring | $58.69 | 2023-2025 | Hizentra |
| Avion Pharmaceuticals | $50.69 | 2022-2023 | Dhivy |
| Vanda Pharmaceuticals INC. | $48.49 | 2025 | Ponvory |
| Ge Healthcare | $44.52 | 2021-2022 | |
| Corium, LLC | $42.24 | 2023 | Adlarity |
| Amneal Pharmaceuticals LLC | $42.04 | 2021-2024 | Crexont |
| Axsome Therapeutics, INC. | $41.94 | 2025 | Symbravo |
| Chiesi USA, INC. | $40.25 | 2024-2025 | Cleviprex |
| Avanir Pharmaceuticals, INC. | $27.49 | 2021 | |
| Grifols USA, LLC | $17.43 | 2023 | Gamunex-C |
| E.R. Squibb & Sons, L.L.C. | $14.27 | 2021 | |
| Biodelivery Sciences International, INC. | $12.21 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunaid Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.